START Taps Preclinical Veteran Smith to Scale Oncology Drug Development Platform
Event summary
- START appoints Dr. Frank Smith as President of XenoSTART, its preclinical research business unit, effective February 24, 2026.
- Smith brings operational and scientific experience from Charles River, GSK, and Champions Oncology to scale XenoSTART's PDX platform.
- XenoSTART operates with over 2,800 patient-derived xenograft (PDX) models spanning various tumor types and disease stages.
- Smith will focus on advancing operations, investing in talent, and deepening partnerships with biopharma sponsors.
The big picture
The appointment underscores START's push to strengthen its preclinical capabilities as oncology drug developers increasingly rely on clinically relevant models for faster, more confident decision-making. Smith's background in scaling complex preclinical organizations positions XenoSTART to capture a larger share of the growing translational research market.
What we're watching
- Operational Scaling
- How Smith's operational discipline will accelerate XenoSTART's ability to deliver decision-quality preclinical data.
- Competitive Positioning
- Whether START can sustain its leadership in oncology translational research amid growing competition.
- Biopharma Partnerships
- The pace at which XenoSTART deepens collaborations with global biopharma sponsors to drive faster drug development.
Our editorial coverage:
Related topics